Search Results - "FEARN, P"

Long-term outcome among men with conservatively treated localised prostate cancer by CUZICK, J, FISHER, G, SCARDINO, P, KATTAN, M. W, BERNEY, D, OLIVER, T, FOSTER, C. S, MØLLER, H, REUTER, V, FEARN, P, EASTHAM, J

“…Optimal management of clinically localised prostate cancer presents unique challenges, because of its highly variable and often indolent natural history. There…”
Get full text

Factors influencing the participation of older people in clinical trials — data analysis from the MAVIS trial by Fearn, P., Avenell, A., Mccann, S., Milne, A. C., Maclennan, G.

“…Background Older people are less likely to be included in clinical trials. Little is known about factors influencing older people’s decisions about…”
Get full text

Pitfalls in the diagnosis of prostatic cancer: retrospective review of 1791 cases with clinical outcome by Berney, D M, Fisher, G, Kattan, M W, Oliver, R T D, Møller, H, Fearn, P, Eastham, J, Scardino, P, Cuzick, J, Reuter, V E, Foster, C S

“…Aims:  To assess the possible reasons for error in the diagnosis of prostatic cancer with available follow‐up data. Method and results:  A cohort of 1791 cases…”
Get full text

Potency after permanent prostate brachytherapy for localized prostate cancer by Potters, L, Torre, T, Fearn, P A, Leibel, S A, Kattan, M W

“…The evaluation of potency preservation after treatment of localized prostate cancer with transperineal permanent prostate brachytherapy (PPB) and the efficacy…”
Get more information

The definition of biochemical failure in patients treated with definitive radiotherapy by Kattan, M W, Fearn, P A, Leibel, S, Potters, L

“…The American Society for Therapeutic Radiology and Oncology (ASTRO) published a definition for biochemical failure following treatment of prostate cancer…”
Get more information

Time trade-off utility modified to accommodate degenerative and life-threatening conditions by Kattan, M W, Fearn, P A, Miles, B J

“…The time trade-off is often argued to be the preferred utility assessment method. When measuring current health in its classic form, it involves a comparison…”
Get full text

The role of external radiotherapy in patients treated with permanent prostate brachytherapy by Potters, L, Fearn, P, Kattan, M

“…To examine the difference in Prostate Specific Antigen (PSA)-Relapse Free Survival (RFS) in patients (pts) with prostate cancer treated with permanent prostate…”
Get full text

12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer by Potters, Louis, Morgenstern, Carol, Calugaru, Emil, Fearn, Paul, Jassal, Anup, Presser, Joseph, Mullen, Edward

“…We reviewed the outcomes in men treated with permanent prostate brachytherapy (PPB). A total of 1,449 consecutive patients with a mean age of 68 years treated…”
Get more information

Enhancing the Reporting of Radiation Oncology Treatment Details to Central Cancer Registries and the SEER Program: A Report of Pilot Studies in Progress by Potters, L., Fearn, P., Chergui, J., Christodouleas, J.P., Disawal, S., Lam, C., Leone, M., May, C., Mogavero, J., Phillips, M.H., Schymura, M., Solis, A., Teckie, S., van der Pas, M., Penberthy, L.

Get full text

Telephone interviews vs. workstation sessions for acquiring quality of life data by Kattan, M W, Fearn, P A, Cantor, S B, Hu, J, Cowen, M E, Giesler, R B, Miles, B J

“…Patient quality of life data can be acquired in a variety of ways, including over the telephone and through computerized questionnaires. However, if the method…”
Get full text

A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy by Potters, L, Cao, Y, Calugaru, E, Torre, T, Fearn, P, Wang, X H

“…The American Brachytherapy Society recommends that postprostate implant dosimetry be performed on all patients undergoing transperineal interstitial permanent…”
Get more information

Evaluation of an Online Platform for Cancer Patient Self-reporting of Chemotherapy Toxicities by Basch, Ethan, Artz, David, Iasonos, Alexia, Speakman, John, Shannon, Kevin, Lin, Kai, Pun, Charmaine, Yong, Henry, Fearn, Paul, Barz, Allison, Scher, Howard I., McCabe, Mary, Schrag, Deborah

“…The current mechanism for monitoring toxicity symptoms in cancer trials depends on a complex paper-based process. Electronic collection of patient-reported…”
Get full text

Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer by Kattan, Michael W, Potters, Louis, Blasko, John C, Beyer, David C, Fearn, Paul, Cavanagh, William, Leibel, Steve, Scardino, Peter T

“…Objectives. To develop a prognostic nomogram to predict the freedom from recurrence for patients treated with permanent prostate brachytherapy for localized…”
Get full text

Importance of implant dosimetry for patients undergoing prostate brachytherapy by Potters, Louis, Huang, David, Calugaru, Emel, Fearn, Paul, Lee, Lucille, Kattan, Michael W.

“…To evaluate the disease and treatment-related factors for predicting biochemical freedom from recurrence (BFR) in patients with clinically localized prostate…”
Get full text

Long-term toxicity monitoring via electronic patient reported outcomes in end-stage chemotherapy patients by Basch, E. M., Iasonos, A., Barz, A., Culkin, A., Kris, M. G., Artz, D., Fearn, P., Speakman, J., Scher, H. I., Schrag, D.

“…Abstract only 9025 Background: In cancer trials, clinicians are required to report patient toxicity symptoms using the NCI's Common Terminology Criteria for…”
Get full text

The prognostic significance of Gleason Grade in patients treated with permanent prostate brachytherapy by Potters, Louis, Purrazzella, Rosemary, Brustein, Sheryl, Fearn, Paul, Huang, David, Leibel, Steven A, Kattan, Michael W

“…To assess the difference in biochemical freedom from relapse (BFR) between patients with clinically localized prostate cancer having Gleason Grade (GG) 3 + 4…”
Get more information

The probability of a positive bone scan in patients who were treated with adrogen ablasio therapy for rising PSA after radical prostatectomy by Dotan, Z. A., Sathyamoorthy, K., Bianco, F. J., Stephenson, A. J., Eastham, J. A., Fearn, P., Schöder, H., Scher, H. I., Scardino, P. T., Kattan, M. W.

“…Abstract only 4574 Background: Physicians often order periodic bone scans to check for metastases in patients treated with androgen ablation therapy (ADT) for…”
Get full text

Predicting time to metastatic progression from biochemical recurrence after radical prostatectomy by Dotan, Z. A., Bianco, F. J., Scardino, P. T., Eastham, J. A., Fearn, P., Scher, H. I., Kattan, M. W.

“…Abstract only…”
Get full text

Predicting time to metastatic progression from biochemical recurrence after radical prostatectomy by Dotan, Z. A., Bianco, F. J., Scardino, P. T., Eastham, J. A., Fearn, P., Scher, H. I., Kattan, M. W.

“…Abstract only…”
Get full text

Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy by Stephenson, Andrew J, Scardino, Peter T, Bianco, Jr, Fernando J, DiBlasio, Christopher J, Fearn, Paul A, Eastham, James A

“…Few patients with locally recurrent prostate cancer after external beam (EB) or interstitial (I) radiotherapy (RT) are considered candidates for salvage…”
Get more information